Osvaren (Magnesium Carbonate Heavy, Calcium Acetate)

Magnesium carbonate heavy (hydrous), the active ingredient in Osvaren, is a phosphate binder presented as a powder for oral use. It binds dietary phosphate in the gastrointestinal tract, helping to control serum phosphate levels in patients with chronic kidney disease. GNH USA supplies Osvaren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and dialysis clinics worldwide.

GNH USA supplies Osvaren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and dialysis clinics worldwide.

Osvaren is a phosphate‑binding agent used in the management of disorders that involve elevated serum phosphate.

- Chronic kidney disease (CKD): helps lower the serum phosphate concentration. - End‑stage renal disease (ESRD) on dialysis: assists in maintaining target phosphate levels. - Hyperphosphatemia secondary to renal failure: reduces phosphate absorption from the gut. - Post‑transplant hyperphosphatemia: supports phosphate control after kidney transplantation. - Dietary phosphate overload: aids in limiting phosphate uptake from meals.

Osvaren may cause gastrointestinal and metabolic reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: occasional mild nausea. - Abdominal discomfort: cramping or bloating. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Metallic taste: transient metallic sensation in the mouth.

Serious or Rare Side Effects: - Hypermagnesemia: elevated magnesium levels, especially in patients with severe renal impairment. - Hypercalcemia: excess calcium accumulation. - Severe abdominal pain: persistent or worsening pain. - Allergic reaction: rash, itching, or swelling. - Electrolyte imbalance: significant shifts in calcium or magnesium balance.

When using Osvaren, consider the following safety measures:

- Renal function monitoring: assess serum phosphate, calcium and magnesium regularly. - Electrolyte balance: watch for signs of hypercalcemia or hypermagnesemia. - Concomitant phosphate binders: avoid simultaneous use with other oral phosphate binders without medical guidance. - Gastrointestinal disorders: use cautiously in patients with bowel obstruction or severe constipation. - Pregnancy and lactation: evaluate risk‑benefit ratio before prescribing. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Osvaren can affect the absorption or activity of several co‑administered medicines.

Major Interactions (Avoid): - Iron supplements: may reduce phosphate‑binder efficacy and vice versa. - Tetracycline antibiotics: binding may lower antibiotic absorption. - Oral bisphosphonates: concurrent use can impair bisphosphonate uptake.

Moderate Interactions (Monitor Closely): - Calcium‑containing antacids: may increase calcium load. - Vitamin D analogues: risk of hypercalcemia when combined. - Loop diuretics: may exacerbate electrolyte shifts. - Proton pump inhibitors: potential alteration of gastric pH affecting binder performance. - Oral potassium supplements: monitor serum potassium levels.